Last €106.69 EUR
Change Today +0.43 / 0.40%
Volume 0.0
BR6 On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 2:13 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

cr bard inc (BR6) Snapshot

Open
€106.67
Previous Close
€106.26
Day High
€106.72
Day Low
€106.67
52 Week High
05/20/14 - €109.00
52 Week Low
08/19/13 - €83.40
Market Cap
8.1B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
76.3M
EX-Date
07/17/14
P/E TM
--
Dividend
€0.88
Dividend Yield
0.58%
Current Stock Chart for CR BARD INC (BR6)

cr bard inc (BR6) Related Businessweek News

No Related Businessweek News Found

cr bard inc (BR6) Details

C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. It offers vascular products, including percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, covered stents, and vascular grafts; vena cava filters; biopsy devices; and temporary pacing electrode catheters for the treatment of peripheral vascular disease and heart arrhythmias. The company’s urology products include Foley catheters to reduce the rate of urinary tract infections; surgical slings to treat stress urinary incontinence; fecal incontinence products; devices for the treatment of pelvic floor and vaginal prolapse; brachytherapy services, devices, and radioactive seeds to treat prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems; ureteral stents; specialty devices for stone removal; catheter stabilization devices; and products for therapeutic hypothermia. It also provides specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters, and enteral feeding devices to treat and manage various cancers and other diseases and disorders. In addition, the company offers surgical specialty products, such as implanted grafts and fixation devices for hernia and soft tissue repair products; surgical sealants for intraoperative sealing of air leaks in thoracic surgery; and other products that include irrigation, wound drainage, and original equipment manufacturers’ products. It sells its products directly to hospitals, individual healthcare professionals, extended care facilities, and alternate site facilities, as well as through hospital/surgical supply and other medical specialty distributors. C. R. Bard, Inc. was founded in 1907 and is headquartered in Murray Hill, New Jersey.

13,000 Employees
Last Reported Date: 02/19/14
Founded in 1907

cr bard inc (BR6) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.1M
President, Chief Operating Officer and Direct...
Total Annual Compensation: $887.0K
Group President
Total Annual Compensation: $660.0K
Group President
Total Annual Compensation: $560.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $540.0K
Compensation as of Fiscal Year 2013.

cr bard inc (BR6) Key Developments

C. R. Bard, Inc. Announces Circulatory System Devices Advisory Panel's Favorable Recommendation to FDA for the Lutonix(R) Drug Coated Balloon

C. R. Bard Inc. announced that the U.S. Food and Drug Administration's (FDA) Circulatory System Devices Advisory Panel provided a unanimous favorable recommendation to FDA for use of the Lutonix(R) Drug Coated Balloon PTA Catheter (DCB) in the U.S. The Lutonix(R) DCB is currently under review by FDA for improving luminal diameter and reducing the incidence of restenosis for the treatment of obstructive de novo or non-stented restenotic lesions (<= 15 cm in length) in native femoropopliteal arteries with reference vessel diameters of 4 mm to 6 mm. If approved, it is expected that the Lutonix(R) DCB will be the first and only FDA-approved DCB available in the U.S. Data presented at June 12, 2014 advisory committee meeting included one-year primary endpoint data from the LEVANT 2 pivotal study, which is a global, prospective, single-blind, randomized, 54-site study (42 sites in the U.S. and 12 in Europe) that enrolled all patients under one protocol. LEVANT 2 investigators have submitted a manuscript for publication with a top-tier medical journal. At one year, LEVANT 2 demonstrated superior primary patency of the target lesion with the Lutonix(R) DCB for the efficacy endpoint (73.5% vs. 56.8%, p<0.001 by Kaplan-Meier time-to-event analysis) and non-inferiority for the safety endpoint; both endpoints were compared to standard percutaneous transluminal balloon angioplasty (PTA). The secondary efficacy endpoint results at one year for patients randomized to treatment with the Lutonix(R) DCB demonstrated superiority in binary restenosis (26.5% vs. 43.2%, p<0.001 by Kaplan-Meier time-to-event analysis at 365 days) when compared to uncoated balloons, and measurable but not statistically significant improvement in freedom from target lesion revascularization (TLR) (89.7% vs. 84.8%, p=0.1673 by Kaplan-Meier time-to-event analysis). Comparing results to other trials can be challenging and misleading, as each study may have varying patient profiles, protocol structures and other criteria that may affect the reported outcomes. LEVANT 2 raises the bar for scientific rigor in superficial femoral artery (SFA) trials and was designed to reduce bias in the results in order to accurately and scientifically assess and compare the long-term performance of key clinical measures. Two key aspects of the study design differentiate this trial from recent SFA studies. First, unlike some other SFA trials, the LEVANT 2 clinical trial did not count bail-out stenting as a primary patency or TLR failure. Second, to reduce the potential introduction of bias into the subjective clinical decision for revascularization, the protocol required the clinical assessment to be performed by a physician who was blinded to the treatment group and the doppler patency measurement. This methodology of blinding the evaluating physicians in SFA trials is unique to LEVANT 2. Published data suggest that trials with less rigorous blinding methodologies have shown physicians to intervene more often in the control arm than in the treatment arm, even when presented with similar objective results such as binary restenosis. This can have a significant impact on subjective results, such as TLR. For example, the blinding methodology in LEVANT 2 showed very similar rates of intervention when binary restenosis occurred in either arm of the trial. If instead the evaluating physicians in LEVANT 2 had intervened at the rates in unblinded DCB trials when binary restenosis occurred (as estimated from public data), the company estimates the comparable freedom from TLR for LEVANT 2 could have been approximately 94% in the treatment arm compared to approximately 78% in the control arm at one year. PTA balloons are a well-established and accepted treatment for peripheral arterial disease (PAD) according to the American College of Cardiology and American Heart Association guidelines. The Lutonix(R) DCB is a standard angioplasty balloon that is coated with a low dose of the anti-restenotic agent, paclitaxel, and is designed as adjunct therapy to standard mechanical dilatation of the vessel to restore blood flow. Successful treatment of PAD in the femoropopliteal arteries requires improved blood flow (patency) for longer periods of time. PTA is typically the first and preferred method to treat patients with PAD. The FDA will consider the positive recommendation of the advisory panel in its review of the PreMarket Approval (PMA) Application that was submitted by C. R. Bard in November 2013. Currently, the Lutonix(R) DCB is available commercially in Europe.

C. R. Bard, Inc. Announces Increase in Regular Quarterly Dividend, Payable on August 1, 2014

The Board of Directors of C. R. Bard Inc. increased the quarterly dividend on Bard's common stock by 5%, to 22 cents per share. The dividend is payable on August 1, 2014 to shareholders of record at the close of business on July 21, 2014.

CR Bard Mulls Acquisitions

CR Bard Inc. (NYSE:BCR) is looking for acquisitions. Regarding acquisitions, Chairman and Chief Executive Officer, Tim Ring said, “I'll take the M&A question first and then I will turn it over to John DeFord for the biosurgery investment question. The M&A issue, we have some fairly strict filters that we go through, market growth rate opportunity being number one. Number two, is that sustainable amongst the top couple. And we'll continue to look at it and evaluate opportunities in that light.”

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BR6:GR €106.69 EUR +0.43

BR6 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CareFusion Corp $44.81 USD +0.17
Edwards Lifesciences Corp $87.94 USD -0.21
Endo International PLC $65.74 USD -0.56
Varian Medical Systems Inc $85.14 USD -0.12
View Industry Companies
 

Industry Analysis

BR6

Industry Average

Valuation BR6 Industry Range
Price/Earnings 15.8x
Price/Sales 3.6x
Price/Book 5.4x
Price/Cash Flow 14.9x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CR BARD INC, please visit www.crbard.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.